Infectious Diseases News and Research

RSS

Vical announces issuance of US patent for HSV-2 vaccine

Vical Incorporated announced today the issuance of U.S. Patent No. 7,879,339, assigned to Vical and the University of Washington, covering DNA vaccines for herpes simplex virus type 2.

9 Feb 2011

Babies born to HIV-infected mothers have lower antibody levels against bacterial infections

Babies whose mothers have HIV, but who are not HIV-infected themselves, are born with lower levels of specific proteins in their blood called antibodies, which fight infection, compared with babies not exposed to HIV, a new study has found.

9 Feb 2011

Total flu cover with one shot

In a medical breakthrough, English scientists have developed a so-called “universal” vaccine to influenza - one that protects against all strains of the potentially deadly illness. This would do away with the need for a new vaccine each flu season they say. Seasonal flu affects up to 20 percent of the population and kills an average of 24,600 people each year. This vaccine would act against swine flu as well assure researchers.

8 Feb 2011

Tufts announces public launch of Institute for Biomedical Partnerships, HUB website

Tufts University today announced the public launch of the Tufts Institute for Biomedical Partnerships website/HUB: www.tuftspharmapartners.org.

8 Feb 2011

Abbott launches PLEX-ID Biothreat Assay to detect, distinguish 17 different pathogens

Abbott announced today that it has introduced the PLEX-ID Biothreat Assay, which is designed to detect and distinguish 17 different biothreat pathogens.

7 Feb 2011

TOMI announces joint venture agreement with Zera Investments

TOMI Environmental Solutions, Inc., a global green leader in infectious disease control and surface and air remediation, announced today a joint venture agreement with Zera Investments PTE. LTD, a Singapore private investment company.

7 Feb 2011

Human Vaccines journal publishes paper on Inovio's new DNA vaccine delivery technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its new generation DNA vaccine delivery technology, which provides the powerful enabling capabilities of electroporation without contacting the skin, is highlighted in a paper published in the scientific journal Human Vaccines.

7 Feb 2011

Studies show growing problems of non-communicable diseases in low-, middle-income countries

Obesity rates have doubled worldwide since 1980," according to a study published Friday as part of a series in the Lancet that also looked at global blood pressure and cholesterol trends, ABC News reports (Carolo, 2/4).

5 Feb 2011

Dermatologists advise parents of young children about atopic dermatitis, food allergies

Atopic dermatitis, one of the most common forms of eczema in this family of inflammatory skin diseases, is a chronic disease marked by red, cracked and itchy skin. Now, increasing evidence indicates atopic dermatitis is a precursor to allergic diseases rather than a consequence. Dermatologists are advising parents of infants and young children affected by this common skin condition to be aware of the potential for future food allergies.

5 Feb 2011

Research roundup: Comparing profit and nonprofit hospice care; Hospital mortality and spending; High-deductible insurance plans

Association Of Hospice Agency Profit Status With Patient Diagnosis, Location of Care, and Length of Stay - "The current Medicare Hospice Benefit reimburses hospices at a fixed per diem rate that does not consider the patient's diagnosis, location of care, or hospice LOS [length-of-stay]," and as such, "profit can be maximized by caring for patients with certain diagnoses that require fewer skilled services, patients residing in nursing homes, or patients with longer hospice stays."

4 Feb 2011

Merck reports GAAP net income of $861 million for 2010

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses.

4 Feb 2011

FIND, Cepheid collaborate to develop rapid molecular test for measurement of HIV viral load

Cepheid and FIND today announced a new collaboration to accelerate the development of a rapid molecular test for the measurement of human immunodeficiency virus viral load.

3 Feb 2011

New England Journal publishes fidaxomicin Phase 3 trial results against CDI

Optimer Pharmaceuticals, announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company's novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection.

3 Feb 2011

First therapeutic vaccine designed from dendritic cells of patient achieves significant response

The therapeutic vaccines are a priority research line of the HIVACAT, the catalan programme for the development of therapeutic vaccines and prevention against the Human Immunodeficiency Virus (HIV). This type of therapeutic vaccine helps the patients who are carriers of the virus, combat infection and control the appearance of AIDS in the same way as with the current antiretroviral treatments.

3 Feb 2011

Researchers develop hard X-ray laser to determine structure of biomolecules

Unraveling the molecular basis of life is an age-old quest of humanity. A breakthrough towards this goal was reported in a pair of studies published Feb. 3 in the scientific journal Nature, detailing a new method developed to determine structures of biomolecules based on diffraction from protein nanocrystals that are so small that they are not even visible under the microscope.

3 Feb 2011

Fidaxomicin demonstrates 45% reduction in recurrences vs. existing treatment for C. difficile infection

Clostridium difficile infection (CDI) is a significant and growing problem in hospitals and other health care facilities, but no new drugs to treat the condition have been developed in several decades. However, a large-scale, phase 3 trial conducted by Canadian and U.S. researchers shows that the new antibiotic Fidaxomicin is superior to existing treatments, demonstrating a 45 percent reduction in recurrences vs. the existing licensed treatment.

3 Feb 2011

Researchers discover potential vaccine capable of reducing H. pylori colonization

A new study led by researchers at Rhode Island Hospital in collaboration with the University of Rhode Island and EpiVax. Inc, a privately owned vaccine development company in Providence, RI, has identified a potential vaccine capable of reducing colonization of Helicobacter pylori -- a known cause of gastritis, ulcer disease and cancer.

2 Feb 2011

New study examines role of later acquisition of hepatitis C in HIV patients

Hepatitis C is a leading cause of illness and death for individuals infected with both HIV and hepatitis C. Recent reports from around the world demonstrate that hepatitis C is emerging as a sexually transmitted infection among HIV-infected men who do not inject drugs. However, many HIV-infected men do not receive continued screening for hepatitis C throughout their HIV care.

2 Feb 2011

Inovio publishes scientific paper detailing SynCon DNA vaccine preclinical study for prostate cancer

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of Inovio's SynCon DNA vaccine for prostate cancer targeting two antigens.

2 Feb 2011

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Aphios® Corporation today announced that it has entered into a subcontract with SAIC-Frederick, a subsidiary of Science Applications International Corporation, to develop phospholipid nanoencapsulated camptothecin, Camposomes™, for the treatment of pancreatic and other cancers, supporting the NCI Alliance for Nanotechnology.

2 Feb 2011

Infectious Diseases News and Research

Vical announces issuance of US patent for HSV-2 vaccine

Babies born to HIV-infected mothers have lower antibody levels against bacterial infections

Total flu cover with one shot

Tufts announces public launch of Institute for Biomedical Partnerships, HUB website

Abbott launches PLEX-ID Biothreat Assay to detect, distinguish 17 different pathogens

TOMI announces joint venture agreement with Zera Investments

Human Vaccines journal publishes paper on Inovio's new DNA vaccine delivery technology

Studies show growing problems of non-communicable diseases in low-, middle-income countries

Dermatologists advise parents of young children about atopic dermatitis, food allergies

Research roundup: Comparing profit and nonprofit hospice care; Hospital mortality and spending; High-deductible insurance plans

Merck reports GAAP net income of $861 million for 2010

FIND, Cepheid collaborate to develop rapid molecular test for measurement of HIV viral load

New England Journal publishes fidaxomicin Phase 3 trial results against CDI

First therapeutic vaccine designed from dendritic cells of patient achieves significant response

Researchers develop hard X-ray laser to determine structure of biomolecules

Fidaxomicin demonstrates 45% reduction in recurrences vs. existing treatment for C. difficile infection

Researchers discover potential vaccine capable of reducing H. pylori colonization

New study examines role of later acquisition of hepatitis C in HIV patients

Inovio publishes scientific paper detailing SynCon DNA vaccine preclinical study for prostate cancer

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News